Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.96)
# 3,137
Out of 5,148 analysts
119
Total ratings
30.91%
Success rate
-3.68%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $8.16 | +59.31% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $16.91 | +89.24% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $3.21 | +180.37% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $108.18 | -12.18% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $15.52 | +61.08% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $4.89 | +145.40% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $8.78 | +36.67% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $3.62 | +93.37% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.44 | +38.89% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $14.58 | +16.60% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $2.37 | +279.75% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $20.44 | +125.05% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.15 | +595.65% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $31.73 | -24.36% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.56 | +56.25% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.51 | +38.25% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.03 | +317.50% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.08 | +292.16% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.68 | +108.33% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.21 | +1,073.71% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.76 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $10.08 | +2,462.50% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $8.16
Upside: +59.31%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $16.91
Upside: +89.24%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $3.21
Upside: +180.37%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $108.18
Upside: -12.18%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.52
Upside: +61.08%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $4.89
Upside: +145.40%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $8.78
Upside: +36.67%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $3.62
Upside: +93.37%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.44
Upside: +38.89%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $14.58
Upside: +16.60%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $2.37
Upside: +279.75%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $20.44
Upside: +125.05%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.15
Upside: +595.65%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $31.73
Upside: -24.36%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.56
Upside: +56.25%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $6.51
Upside: +38.25%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $5.03
Upside: +317.50%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.08
Upside: +292.16%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.68
Upside: +108.33%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.21
Upside: +1,073.71%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.76
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $10.08
Upside: +2,462.50%